ASO VISUAL ABSTRACT

ASO Visual Abstract: Limited Prognostic Value of KRAS for Patients Undergoing Hepatectomy for Colorectal Liver Metastases

Yoshinori Takeda, MD, PhD^{1,2}, Yoshihiro Mise, MD, PhD^{1,2}, Yu Takahashi, MD, PhD², Hiromichi Ito, MD, FACS², Yosuke Inoue, MD, PhD², Ryuji Yoshioka, MD, PhD¹, Yoshihiro Ono, MD, PhD², and Akio Saiura, MD, PhD^{1,2}

¹Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Hongo, Tokyo, Japan;

²Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan

This multi-center retrospective study showed that the prognostic value of KRAS mutation status after initial hepatectomy for colorectal liver metastases was demonstrated only for patients who received preoperative

chemotherapy and those with moderate tumor burden. (<https://doi.org/10.1245/s10434-021-11015-9>).

DISCLOSURES There are no conflicts of interest.